AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ULTRAGENYX PHARMACEUTICAL · Biopharma company

Filing Registration

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted May 24, 2025

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

California

Lobbying activity 1

Health Issues

Rare & ultra-rare disease policy issues, newborn screening, genomic sequencing

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.